RhumbLine Advisers’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-113,415
| Closed | -$5.33M | – | 4185 |
|
|
2025
Q2 | $5.33M | Buy |
113,415
+7,994
| +8% | +$356K | ﹤0.01% | 1380 |
|
|
2025
Q1 | $4.65M | Buy |
105,421
+3,517
| +3% | +$162K | ﹤0.01% | 1397 |
|
|
2024
Q4 | $3.68M | Buy |
101,904
+2,251
| +2% | +$78.6K | ﹤0.01% | 1571 |
|
|
2024
Q3 | $3.19M | Sell |
99,653
-5,003
| -5% | -$187K | ﹤0.01% | 1649 |
|
|
2024
Q2 | $3.94M | Buy |
104,656
+5,081
| +5% | +$214K | ﹤0.01% | 1518 |
|
|
2024
Q1 | $4.9M | Buy |
99,575
+4,511
| +5% | +$209K | ﹤0.01% | 1432 |
|
|
2023
Q4 | $3.47M | Buy |
95,064
+8,672
| +10% | +$226K | ﹤0.01% | 1627 |
|
|
2023
Q3 | $2M | Buy |
86,392
+6,345
| +8% | +$174K | ﹤0.01% | 1858 |
|
|
2023
Q2 | $2.1M | Buy |
80,047
+22,056
| +38% | +$580K | ﹤0.01% | 1877 |
|
|
2023
Q1 | $1.49M | Sell |
57,991
-62
| -0.1% | -$1.81K | ﹤0.01% | 1960 |
|
|
2022
Q4 | $1.51M | Buy |
58,053
+4,939
| +9% | +$122K | ﹤0.01% | 1935 |
|
|
2022
Q3 | $1.51M | Buy |
53,114
+4,753
| +10% | +$136K | ﹤0.01% | 1923 |
|
|
2022
Q2 | $1.19M | Buy |
48,361
+17,732
| +58% | +$648K | ﹤0.01% | 2054 |
|
|
2022
Q1 | $1.73M | Buy |
30,629
+1,101
| +4% | +$63K | ﹤0.01% | 1888 |
|
|
2021
Q4 | $1.83M | Buy |
29,528
+140
| +0.5% | +$9.27K | ﹤0.01% | 1935 |
|
|
2021
Q3 | $1.86M | Buy |
29,388
+928
| +3% | +$71.5K | ﹤0.01% | 1949 |
|
|
2021
Q2 | $2.35M | Buy |
28,460
+2,398
| +9% | +$182K | ﹤0.01% | 1879 |
|
|
2021
Q1 | $1.92M | Sell |
26,062
-1,775
| -6% | -$139K | ﹤0.01% | 1942 |
|
|
2020
Q4 | $2.02M | Buy |
27,837
+3,631
| +15% | +$234K | ﹤0.01% | 1839 |
|
|
2020
Q3 | $1.15M | Sell |
24,206
-3,438
| -12% | -$146K | ﹤0.01% | 1934 |
|
|
2020
Q2 | $1.16M | Buy |
27,644
+15,392
| +126% | +$548K | ﹤0.01% | 1985 |
|
|
2020
Q1 | $331K | Buy |
12,252
+2,826
| +30% | +$92.1K | ﹤0.01% | 2354 |
|
|
2019
Q4 | $363K | Buy |
+9,426
| New | +$221K | ﹤0.01% | 2504 |
|
Other funds holding SWTX
RhumbLine Advisers's SWTX Position: Q3 2025 in Review
RhumbLine Advisers sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 113,415 shares — an estimated $5.33M sold.
RhumbLine Advisers first reported a position in SWTX in Q4 2019 and held it in 23 quarters. The position peaked at $5.33M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- RhumbLine Advisers reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- RhumbLine Advisers sold 113,415 SpringWorks Therapeutics shares in Q3 2025, an estimated $5.33M.
- RhumbLine Advisers first reported a position in SpringWorks Therapeutics in Q4 2019 and held it in 23 quarters.
- RhumbLine Advisers's SpringWorks Therapeutics position peaked at $5.33M in Q2 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.